-+ 0.00%
-+ 0.00%
-+ 0.00%

Immunic Presents Plans for Mid-2027 US Filing for MS Drug Vidofludimus Calcium

PUBT·11/13/2026 20:06:07
Listen to the news
Immunic Presents Plans for Mid-2027 US Filing for MS Drug Vidofludimus Calcium
  • Immunic expects December 2026 top-line data from fully enrolled Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing multiple sclerosis.
  • Positive results would support a targeted mid-2027 US regulatory submission, with potential approval in 2028.
  • The Phase 3 PROTECT-MS trial in progressive multiple sclerosis is expected to enroll its first patient in the first half of 2027.
  • Funding is expected to last into late 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.